Literature DB >> 31478797

Impacts of the prostate stem cell antigen (PSCA) and Clostridium perfringens enterotoxin (CPE) on the apoptosis and cell cycle regulatory genes in PC3.

Saied Abedi1, Abbas Doosti2, Mohammad-Saied Jami3,4.   

Abstract

Clostridium perfringens enterotoxin (CPE) has anti-prostate cancer effects and the prostate stem cell antigen (PSCA) has been used as a plasmid-based vaccine. So we expressed both of them in the PC3 cells to evaluate their effects on cell cycling and apoptosis. The PC3 cells were transfected either by the pBudCE4.1-CPE-PSCA or empty plasmid. The expression of the cpe and PSCA genes in transfected PC3 was evaluated. The apoptosis genes (Fas, P53, Bak, and Bax) as well as cell cycling genes (cyclin D1 and E) expression was evaluated by qPCR. Successful expression of cpe and PSCA in PC3 cells was confirmed. The flow cytometry results showed the cellular death rates of 62.6% and 21.8% for PC3 cells transformed with recombinant and empty plasmids respectively. Bak, Fas, Bax and P53 genes were significantly upregulated in PC3 cells transformed with pBudCE4.1-CPE-PSCA, while cyclin D1 and E were downregulated when compared with the pBudCE4.1-transfected PC3 and normal cells (p < .05). The results showed the lethal consequences of cpe and PSCA genes expression on PC3 transfected cells. Expression of the cpe and PSCA genes affects the PC3 cell death so it could be a suitable candidate for further researches in prostate cancer vaccine development.

Entities:  

Keywords:  Clostridium perfringens enterotoxin (CPE); PC3; apoptosis; cell cycling genes; prostate cancer; prostate stem cell antigen (PSCA)

Year:  2019        PMID: 31478797     DOI: 10.1080/10826068.2019.1660892

Source DB:  PubMed          Journal:  Prep Biochem Biotechnol        ISSN: 1082-6068            Impact factor:   2.162


  1 in total

Review 1.  Prostate Microbiota and Prostate Cancer: A New Trend in Treatment.

Authors:  Bangwei Che; Wenjun Zhang; Shenghan Xu; Jingju Yin; Jun He; Tao Huang; Wei Li; Ying Yu; Kaifa Tang
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.